Vaxcyte, Inc. (NASDAQ:PCVX) is Windsor Advisory Group LLC's 4th Largest Position

Windsor Advisory Group LLC grew its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 72.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 39,223 shares of the company's stock after acquiring an additional 16,479 shares during the quarter. Vaxcyte accounts for approximately 3.7% of Windsor Advisory Group LLC's holdings, making the stock its 4th largest holding. Windsor Advisory Group LLC's holdings in Vaxcyte were worth $3,211,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Capital Research Global Investors boosted its position in Vaxcyte by 26.8% in the fourth quarter. Capital Research Global Investors now owns 6,210,523 shares of the company's stock valued at $508,393,000 after buying an additional 1,312,302 shares during the last quarter. Norges Bank purchased a new stake in Vaxcyte in the fourth quarter valued at approximately $90,069,000. Vanguard Group Inc. boosted its position in Vaxcyte by 4.6% in the fourth quarter. Vanguard Group Inc. now owns 11,961,687 shares of the company's stock valued at $979,184,000 after buying an additional 521,204 shares during the last quarter. Paradigm Biocapital Advisors LP boosted its position in Vaxcyte by 57.3% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,422,787 shares of the company's stock valued at $116,469,000 after buying an additional 518,255 shares during the last quarter. Finally, Lazard Asset Management LLC purchased a new stake in Vaxcyte in the fourth quarter valued at approximately $39,846,000. Institutional investors and hedge funds own 96.78% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on PCVX. Evercore ISI upgraded Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. The Goldman Sachs Group dropped their target price on Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Bank of America dropped their target price on Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Guggenheim reiterated a "buy" rating and set a $160.00 price target on shares of Vaxcyte in a research report on Wednesday, March 12th. Finally, Cantor Fitzgerald started coverage on Vaxcyte in a research report on Tuesday, April 22nd. They set an "overweight" rating for the company. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $136.50.

Insider Activity

In other news, COO Jim Wassil sold 8,000 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total value of $586,160.00. Following the completion of the sale, the chief operating officer now directly owns 154,931 shares in the company, valued at $11,351,794.37. The trade was a 4.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 3.10% of the company's stock.

Vaxcyte Price Performance

PCVX stock traded down $1.41 during trading on Friday, hitting $32.54. 1,763,863 shares of the company traded hands, compared to its average volume of 1,371,448. The stock's 50-day simple moving average is $38.53 and its 200 day simple moving average is $69.19. The company has a market cap of $4.20 billion, a PE ratio of -7.07 and a beta of 1.27. Vaxcyte, Inc. has a 1 year low of $27.66 and a 1 year high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter in the prior year, the firm posted ($0.85) earnings per share. Research analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.